Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).

被引：0

作者：

Richardson, Debra L.

Barve, Minal A.

Strauss, James Fredric

Ulahannan, Susanna Varkey

Moore, Kathleen N.

Hamilton, Erika Paige

Johnson, Melissa Lynne

Papadopoulos, Kyriakos P.

Zarwan, Corrine

Anderson, Charles K.

Buscema, Joseph

Doroshow, Deborah Blythe

Edenfield, William Jeffery

Matulonis, Ursula A.

Burns, Timothy F.

Huebner, Dirk

Jansen, Valerie Malyvanh

Mosher, Rebecca

Jarlenski, Donna

Tolcher, Anthony W.

机构：

[1] Univ Oklahoma, Hlth Sci Ctr, Sarah Cannon Res Inst, Stephenson Canc Ctr, Oklahoma City, OK USA

[2] Mary Crowley Canc Res Ctr, Dallas, TX USA

[3] Sarah Cannon Res Inst, Nashville, TN USA

[4] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA

[5] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

[6] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA

[7] South Texas Accelerated Res Therapeut LLC, San Antonio, TX USA

[8] Lahey Hosp & Med Ctr, Burlington, MA USA

[9] Willamette Valley Canc Inst, Eugene, OR USA

[10] Arizona Oncol Associates, Tucson, AZ USA

[11] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA

[12] Prisma Hlth Upstate Canc Inst, Inst Translat Oncol Res, Greenville, SC USA

[13] Dana Farber Canc Inst, Boston, MA 02115 USA

[14] Univ Pittsburgh, Med Ctr UPMC, Hillman Canc Ctr, Pittsburgh, PA USA

[15] Mersana Therapeut Inc, Cambridge, MA USA

[16] NEXT Oncol, San Antonio, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3549

引用

页数：2

共 50 条

[1] Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate
Hamilton, E. P.
Barve, M. A.
Tolcher, A. W.
Buscema, J.
Papadopoulos, K. P.
Zarwan, C.
Anderson, C. K.
Doroshow, D.
Wang, D.
Huebner, D.
Jansen, V. M.
Jarlenski, D.
Mosher, R.
Kaufman, J.
Moore, K. N.
Richardson, D. L.
ANNALS OF ONCOLOGY, 2020, 31 : S627 - S628
[2] Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.
Tolcher, Anthony W.
Ulahannan, Susanna Varkey
Papadopoulos, Kyriakos P.
Edenfield, William Jeffery
Matulonis, Ursula A.
Burns, Timothy F.
Mosher, Rebecca
Fielman, Barbara
Hailman, Eric
Burris, Howard A.
Moore, Kathleen N.
Hamilton, Erika Paige
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[3] A phase I study of DNIB0600A, an antibody-drug conjugate (ADC) targeting NaPi2b, in patients (pts) with non-small cell lung cancer (NSCLC) or platinum-resistant ovarian cancer (OC)
Burris, Howard A.
Gordon, Michael S.
Gerber, David E.
Spigel, David R.
Mendelson, David S.
Schiller, Joan H.
Wang, Yulei
Choi, Younleong
Kahn, Robert S.
Wood, Katie
Maslyar, Daniel J.
Infante, Jeffrey R.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[4] Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer
Richardson, Debra
Hamilton, Erika
Barve, Minal
Anderson, Charles
Taylor, Sara
Lakhani, Nehal
Buscema, Joseph
Tolcher, Anthony
Zarwan, Corrine
Werner, Theresa
Hays, John
Arend, Rebecca
Edenfield, Jeffery
Putiri, Emily
Bernardo, Patricia
Burger, Robert
Matulonis, Ursula
GYNECOLOGIC ONCOLOGY, 2022, 166 : S48 - S48
[5] Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting antibody-drug conjugate (ADC), in an unselected panel of human primary ovarian mouse xenograft models
Mosher, Rebecca
Poling, Laura
Qin, LiuLiang
Bodyak, Natalya
Bergstrom, Donald
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
[6] UPGRADE: PHASE 1 COMBINATION TRIAL OF THE NAPI2B-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) UPIFITAMAB RILSODOTIN (UPRI; XMT-1536) IN PATIENTS WITH OVARIAN CANCER
Hays, John
Werner, Theresa
Lakhani, Nehal
Edenfield, Jeffrey
Buscema, Joseph
Burns, Timothy
Carrington, Cassandra
Keeton, Erika
Burger, Robert
Anderson, Charles
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A235 - A235
[7] PHARMACOKINETICS OF ANTIBODY-DRUG CONJUGATE (ADC)-DNIB0600A IN A PHASE I STUDY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER (OC)/NON-SMALL CELL LUNG CANCER (NSCLC).
Xu, J.
Burris, H., III
Gordon, M.
Gerber, D.
Choi, Y.
Lin, K.
Maslyar, D.
Girish, S.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S32 - S32
[8] Upgrade: Phase 1 combination trial of the NaPi2b-directed dolaflexin antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer
Lakhani, Nehal
Burns, Timothy
Barve, Minal
Edenfield, Jeffery
Hays, John
Zarwan, Corrine
Werner, Theresa
Anderson, Charles
Buscema, Joseph
Bernardo, Patricia
Keeton, Erika
Carrington, Cassandra
Burger, Robert
GYNECOLOGIC ONCOLOGY, 2022, 166 : S285 - S286
[9] A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with non- small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC).
Gordon, Michael S.
Gerber, David E.
Infante, Jeffrey R.
Xu, Jian
Shames, David S.
Choi, Younjeong
Kahn, Robert S.
Lin, Kedan
Wood, Katie
Maslyar, Daniel J.
Burris, Howard A.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[10] Optimizing the dose of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC): A post-hoc analysis of a phase 1b expansion study in ovarian cancer
Monk, Bradley
Concin, Nicole
Richardson, Debra
Ray-Coquard, Isabelle
Pothuri, Bhavana
Marth, Christian
Bernardo, Patricia
Burger, Robert
Im, Ellie
Aldairy, Wassim
Coleman, Robert
Mirza, Mansoor
GYNECOLOGIC ONCOLOGY, 2022, 166 : S166 - S166

← 1 2 3 4 5 →